-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Lowering blood sugar can reduce the symptoms of hyperglycemia and many long-term complications of diabetes
diabetes
Addition of dulaglutide 1.
Changes from baseline in HbA1c during treatment and up to 72 months were assessed before and after adjustment for diabetes duration, prior microvascular disease (nephropathy or retinopathy), and BMI
The results showed that HbA1c was significantly lower in patients treated with duraglutide compared with placebo over the 72-month treatment period (least squares mean difference = -0.
Patients receiving duraglutide had significantly lower HbA1c compared with placebo (least squares mean difference = -0.
, but the mean HbA1c value in the duraglutide group was still lower than baseline and lower than the mean HbA1c value in the placebo group
CONCLUSIONS: Dulaglutide 1.
CONCLUSIONS: Dulaglutide 1.
references:
HbA1c Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial.
HbA1c Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial.
Leave a Comment